Eli Lilly’s Valuation after 2Q17 Earnings Release
For 2Q17, Eli Lilly (LLY) surpassed analysts’ EPS estimate of $1.05 and reported EPS of $1.11. Analysts are estimating EPS of $1.03 for 3Q17.
Eli Lilly repurchased shares worth $200.0 million and distributed dividends of more than $500.0 million to its shareholders in 2Q17.
Elanco’s revenues fell 9.0% to $784.8 million during 2Q17 compared to $859.8 million during 2Q16.
Cialis reported nearly flat revenues at $627.3 million in 2Q17 compared to $630.5 million for 2Q16.
Sales of Cymbalta fell ~13.0% to $206.6 million in 2Q17 compared to ~$236.5 million in 2Q16.
Alimta sales fell ~12.0% to $532.9 million in 2Q17 compared to $607.1 million in 2Q16.
Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.
For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.
Growth for the Human Pharmaceuticals segment in 2Q17 was driven by increased sales of products such as Forteo, Humulin, and Effient.
Eli Lilly and Company (LLY) released its 2Q17 earnings on July 25, 2017, reporting an 8.0% rise in its top line to $5.8 billion for 2Q17 compared to 2Q16.
Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.
AstraZeneca’s (AZN) revenue is expected to fall 9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16.
AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.
Analysts expect Bristol-Myers Squibb’s (BMY) top line to rise 4.4% to ~$5.1 billion in 2Q17. They expect its earnings per share to be $0.74 in the quarter.
Bristol-Myers Squibb (BMY) is expected to report a rise of ~4.4% in its earnings to $5.1 billion for 2Q17 on July 27, 2017.
Headquartered in New York City, Bristol-Myers Squibb (BMY) is a leading American pharmaceutical company.
Wall Street analysts estimate that GSK’s top line will rise 11.4% to ~7.3 billion British pounds for 2Q17. Its EPS is expected come in at 0.26 pounds.
Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.
For 2Q17, analysts estimate that GSK’s revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.
For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.